Overview
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive indolealkylamine that is produced by a number of plants and animal, but is best known to be present, along with its active, O-demethylated metabolite bufotenine, in the skin glands of a certain toxic desert toad (Incilius alvarius, formerly Bufo alvarius).
5-MeO-DMT, first synthesized in 1936 (Hoshino 1936), is closely related in structure to serotonin (5-hydroxytryptamine [5-HT]), and therefore has a similar molecular structure to the classic psychedelics DMT (N,N-dimethyltryptamine) and psilocybin. However, its pharmacological activity may be distinct; 5-MeO-DMT works mainly as a selective serotonin receptor agonist at both 5-HT1A and 5-HT2A receptors, with functional dominance of the 5 HT1A subtype being suggested by numerous researchers (Spencer 1987, Winter 2000, Krebs-Thomson 2006, Shen 2010a).
MEO101
Usona has completed all dosing sessions for participants in our phase 1, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), administered by intramuscular injection in healthy volunteers.
To learn more about the study please visit www.clinicaltrials.gov.
Other Drug Development Programs
